Douglas Pharmaceuticals Ltd Graeme Douglas Managing Director
Company history Year Key Event 1967 Trading commences 1972 Frusemide registered 1983 Penicillin plant commissioned (solid oral in ‘85) 1986 Purchase of Karitane product license 1988 Loss of 3 major agencies 1989 First Australian market product registration 1990 Henderson site opened (new plant in 1996) 1996 Sale of Karicare to Nutricia 2002 Isotretinoin first registered in Europe 2006 Sale of Australian subsidiary 2007 FDA Approval 2008 Purchase of nutraceutical business line 2010 Added softgel capacity to manufacturing capabilities
Sales Growth Growth In Revenue 1967 – 2011B (NZ$m’s) CAGR 14%
Registration & Licensing Product Development Process Ideas Product Design Evaluation Detailed Scoping Scale-up Bio-studies Registration & Licensing Launch Company Strategy Market Assessment Patent Search Feasibility API Source Formulation Analytical Validation Pilot Scale Large Scale Validation Stability Regulatory Costings Licensing Stability Clinical Stability G7 G6 G5 G4 G3 18-36 Months NZ$0.5 to 1.5Mn G2 G1 6-12 Months NZ$0.3 to 1Mn 2-10 Months NZ$0.5 to 1.5Mn 12 - 24 Months NZ$0.5 to 2Mn TOTAL (per Project) 3.5 - 7.5 years duration and NZ$ 2.0 to 6.0Mn 3-6 Months NZ$ 70K
Continued Investment in R&D Douglas Pharmaceuticals Turnover and R&D Spend (2004 – 2011B) NZ$M’s NZ$M’s Annual Turnover Annual R&D Spend
Oratane (Isotretinoin Softgel Capsules) Isomer of Vitamin A acid Highly effective treatment for Acne Product is a challenge to develop, manufacture & register Douglas developed the first generic A huge success for Douglas: 40 customers in 26 countries Oratane has annual sales of over NZ$ 40 million
Global Growth Accelerated Product and New Market Growth Are Key Elements of Our 2015 Growth Strategy Existing markets New markets Key Objectives 2010 2015 Number of Douglas Developed Products 23 45 Total Sales Revenues (Domestic and Export) $139m $250m
Thank You